Latest total revenue for CBMG: $320K, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2020
Trailing 12 months ending Sep 2020
The latest total revenue for CBMG is $320K as of September 2020. That compares with $75K in the prior-year period — up 330.8% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Cellular Biomedicine Group's historical trend and sector peers before judging valuation or financial health.
Over the past year, CBMG's total revenue moved from $75K to $320K — a 330.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cellular Biomedicine Group's operating scale or balance-sheet position.
Against Healthcare companies, CBMG currently prints $320K for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cellular Biomedicine Group's growth, margins, and balance sheet.
A total revenue figure of $320K for CBMG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting CBMG's total revenue ($320K), review year-over-year change from $75K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.